

*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

- **Full Name:** Min Hee Hong
 - **Current Position & Affiliation:** Associate Professor
 - **Country:** Korea
-

• **Educational Background:**

Mar 1999 – Feb 2005 Medical Doctor, Yonsei University College of Medicine, Seoul, Korea

Sep 2007 – Aug 2015 Master of Science in Medicine, Yonsei University Graduate School, Seoul, Korea

• **Professional Experience:**

Mar 2005 – Feb 2006 Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Rotating Internship

Mar 2006 – Feb 2010 Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Residency (Specialty: Medical Oncology)

May 2013 – Feb 2014 Division of Medical Oncology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Fellowship

Jun 2015 – Feb 2016 Merck Sharp & Dohme Corp. Medical Affairs - Oncology
- Medical Advisor

Mar 2019 – Feb 2021 Vice Managing Director of Head and Neck Cancer Center, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Yonsei University Health System

Mar 2016 – Feb 2022 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Yonsei University Health System
- Assistant Professor

Mar 2022 - Present Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Yonsei University Health System
- Associate Professor

• **Professional Organizations:**

American Society of Clinical Oncology (ASCO)

European Society for Medical Oncology (ESMO)

Korean Association of Medical Oncology (KSMO)

Korean Cancer Study Group (KCSG)

Korean Cancer Association (KCA)
Korean Association for Lung Cancer (KALC)
Korean Society of Head and Neck Oncology (KSHNO)

• **Main Scientific Publications:**

The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer.

Korean J Intern Med. 2023 Jan 19. doi: 10.3904/kjim.2022.247. Epub ahead of print. PMID: 36650729.

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

Ther Adv Med Oncol. 2022 Feb 26;14:17588359221079125. doi: 10.1177/17588359221079125. PMID: 35251316; PMCID: PMC8891830.

Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.

Cancer Immunol Immunother. 2022 May;71(5):1093-1101. doi: 10.1007/s00262-021-03052-w. Epub 2021 Sep 27. PMID: 34568975.

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study.

Cancers (Basel). 2021 Jul 22;13(15):3681. doi: 10.3390/cancers13153681. PMID: 34359582; PMCID: PMC8345213

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.

Kidney Res Clin Pract. 2021 Sep;40(3):344-354. doi: 10.23876/j.krcp.21.037. Epub 2021 Jul 8. PMID: 34233435; PMCID: PMC8476309.

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Cancers (Basel). 2021 Jun 21;13(12):3096. doi: 10.3390/cancers13123096. PMID: 34205733; PMCID: PMC8234556.

Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy.

Cancers (Basel). 2021 May 22;13(11):2549. doi: 10.3390/cancers13112549. PMID: 34067376; PMCID: PMC8197012.

Dynamic changes in circulating PD-1 + CD8 + T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer.

Eur J Cancer. 2021 Jan;143:113-126. doi: 10.1016/j.ejca.2020.10.028. Epub 2020 Dec 7. PMID: 33302114.

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma.

J Thorac Dis. 2020 Nov;12(11):6426-6434. doi: 10.21037/jtd-20-1088. PMID: 33282345; PMCID: PMC7711420.

Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.

Cancer. 2020 Oct 15;126(20):4521-4531. doi: 10.1002/ncr.33123. Epub 2020 Aug 4. PMID: 32749686.

High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma.

Sci Rep. 2019 Dec 27;9(1):20197. doi: 10.1038/s41598-019-56828-7. PMID: 31882943; PMCID: PMC6934772.

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer.

Yonsei Med J. 2019 Jun;60(6):525-534. doi:10.3349/ymj.2019.60.6.525. PMID: 31124335; PMCID: PMC6536394.